TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06798571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix Oral Tablet
Description: 2 x 200 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol patch
Description: 0.05 mg/day patch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cellulose placebo
Description: placebo tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo patch
Description: placebo patch
Study: NCT06799611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM336 Injection
Description: subcutaneous CM336 administration step-up dosing Dose and frequency of CM336 according to the protocol
Study: NCT06799793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GI Genius
Description: GI Genius software component is an artificial intelligence-based medical device that has been trained to process colonoscopy images containing regions consistent with colorectal lesions such as polyps, including those with flat morphology (nonpolyp).

Intervention type: OTHER
Group type: OTHER
Intervention: Colonscope Olympus
Description: Colonoscopy with one of the Olympus colonoscopes supplied to the IRCCS AOUBO Gastroenterology Unit without the aid of the CAD system
Study: NCT05956314

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Patient global impression of severity (PGI-S) scoring
Description: The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort.~The PGI-S will be evaluated using a 5-point scale from 1 (none) to 5 (very severe) as follows:~Please rate the severity of your disease right now, from 1= none to 5= very severe

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Patient global impression of severity (PGI-S) scoring
Description: The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort.~The PGI-S will be evaluated using a 5-point scale from 1 (none) to 5 (very severe) as follows:~Please rate the severity of your disease right now, from 1= none to 5= very severe

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lesion photography
Description: High quality photographic documentation of the treated lesions will be performed during Screening and on Days 1, 7, 42, 63, 84, 112, and 140, or at an ET visit before treatment - where applicable, per cohort.~The photographs will be taken under standardised conditions, using imitoMeasure (Ⓒ imito AG 2016-2022).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lesion photography
Description: High quality photographic documentation of the treated lesions will be performed during Screening and on Days 1, 7, 42, 63, 84, 112, and 140, or at an ET visit before treatment - where applicable, per cohort.~The photographs will be taken under standardised conditions, using imitoMeasure (Ⓒ imito AG 2016-2022).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KM-001 cream 1% 16 weeks treatment.
Description: KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 112 days. IMP will be applied on the plantar surfaces.
Study: NCT06379685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-190
Description: Propylene glycol 0.3% - Polyethylene glycol 400 0.3%. Ophthalmic solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra®
Description: Propylene glycol 0.3% - Polyethylene glycol 400 0.4%. Ophthalmic solution.
Study: NCT05930548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Shrinkage Giomer
Description: Low shrinkage giomer resin composite shows both sustained fluoride release and recharge, and low volumetric shrinkage of less than 1% with low resultant polymerization shrinkage stress. Such remarkable feature is due to the novel SRS (Steric Repulsion Structured) molecule which is designed to decrease polymerization shrinkage through molecular steric repulsion resulting in a stable restoration microstructure (AlQranei MS et al, 2021). Thus, low shrinkage giomers are best indicated in class V cavities where the dentin bonding agent does not have high strength (Algailani U, et al 2022).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Shrinkage Giomer
Description: Low shrinkage giomer resin composite shows both sustained fluoride release and recharge, and low volumetric shrinkage of less than 1% with low resultant polymerization shrinkage stress. Such remarkable feature is due to the novel SRS (Steric Repulsion Structured) molecule which is designed to decrease polymerization shrinkage through molecular steric repulsion resulting in a stable restoration microstructure (AlQranei MS et al, 2021). Thus, low shrinkage giomers are best indicated in class V cavities where the dentin bonding agent does not have high strength (Algailani U, et al 2022).
Study: NCT06799507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventions Based on Mindfulness
Description: Affirmation, Relaxation, Mindfulness, Meditation, Healthy Lifestyle, Quality Life
Study: NCT06200051

Intervention type: DIAGNOSTIC_TEST
Intervention: Prediction of high risk of cancer
Description: This initiative is aimed at comprehending the incidence rates of these four types of cancers, including lung cancer (LCA), liver cancer (LC), upper gastrointestinal cancer (UGIC), and CRC, to provide a theoretical foundation for the implementation of more practical and effective cancer screening strategies.
Study: NCT06799507

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine clinical procedure
Description: Routine clinical procedure
Study: NCT06798493

Intervention type: OTHER
Intervention: Complex Regional Pain Syndrome (CRPS) Severity Score - Self Report
Description: Self-report tool in a questionnaire format to capture CPRS Severity Score.
Study: NCT06200051

Intervention type: DIAGNOSTIC_TEST
Intervention: Prediction of high risk of cancer
Description: This initiative is aimed at comprehending the incidence rates of these four types of cancers, including lung cancer (LCA), liver cancer (LC), upper gastrointestinal cancer (UGIC), and CRC, to provide a theoretical foundation for the implementation of more practical and effective cancer screening strategies.

Intervention type: DIAGNOSTIC_TEST
Intervention: Prediction of high risk of cancer
Description: This initiative is aimed at comprehending the incidence rates of these four types of cancers, including lung cancer (LCA), liver cancer (LC), upper gastrointestinal cancer (UGIC), and CRC, to provide a theoretical foundation for the implementation of more practical and effective cancer screening strategies.
Study: NCT05465018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Happy Flow / Baseline
Description: Baseline (without make-up or mask)
Study: NCT06454383

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT05465018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Make-up
Description: To test device on participant who is wearing facial make-up

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sunglasses
Description: To test device on participant who is wearing sunglasses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Face mask
Description: To test device on participant who is wearing a facial mask

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimum requirements camera
Description: To test the minimum requirements of the camera
Study: NCT06798311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SUPPORT workbook
Description: The SUPPORT workbook contains a template for how pelvic floor physical therapy is delivered in the typical in-person setting with a combination of education, bladder re-training exercises, pelvic floor stretching and core strengthening. To aid in the demonstration of physical therapy exercises, the workbook includes QR-coded links to videos of a physical therapist performing the exercises in an ideal form. The videos include audio instruction to ensure that patients can learn the concepts in either visual, auditory or written form. The cognitive behavioral therapy (CBT) portion of the workbook is adapted from the standardized CBT protocol and includes short introductions and exercises pertaining to cognitive flexibility, behavioral activation and social support. The total time commitment for the program is 2-hours per week.~Patients also will be given access to a custom programmed GPT trained on the SUPPORT workbook and given instructions on empathetic communication techniques.
Study: NCT06799078

Intervention type: OTHER
Intervention: Observation while participants receive treatment by their primary care provider
Description: Participants complete a consultation with a psychiatrist who makes some recommendations for the treatment of their depression. The participant's primary care provider decides whether to implement some of these recommendations.

Intervention type: OTHER
Intervention: Observation while participants receive treatment by their primary care provider
Description: Participants complete a consultation with a psychiatrist who makes some recommendations for the treatment of their depression. The participant's primary care provider decides whether to implement some of these recommendations.
Study: NCT06798961

Intervention type: PROCEDURE
Intervention: Ablation
Description: Patient treated with an ablation to eliminate the accessory conduction pathway in the heart.

Intervention type: PROCEDURE
Intervention: Standard of care without ablation
Description: Patient diagnosed with accessory pathway but elected against cardiac ablation as a treatment option at the time of diagnosis.
Study: NCT06798428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: group A will receive ultrasound phonophoresis (Glucosamine, Chondroitin and Some Herbs Extract )
Description: Group (A)will have GL, CH and natural herbs phonophoresis .Ultrasound parameters are 1 W/cm for intensity, 1 MHz for frequency and 5 min continuous mode then 5 min pulsed mode. The device that will be used is medserve, England (the head of the device is 5cm).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group B will receive ultrasound with topical gel , same parameter as group A
Description: Ultrasound parameters are 1 W/cm for intensity, 1 MHz for frequency and 5 min continuous mode then 5 min pulsed mode. The device that will be used is medserve, England (the head of the device is 5cm). Topical gel with no drugs

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Group C sham ultrasound for massage - 5 minutes
Description: sham ultrasound for massage - 5 minutes
Study: NCT06798207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2102 for injection
Description: TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC).
Study: NCT05501548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300mg by mouth twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Ascorbic acid 1g/kg administered intravenously twice weekly
Study: NCT06800261

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sinovac PCV24
Description: Sinovac PCV24 (0.5 mL) is administered intramuscularly according to different immunization schedules.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar®
Description: Prevnar® (0.5 mL) is administered intramuscularly according to different immunization schedules.
Study: NCT06797609

Intervention type: OTHER
Intervention: Sample analyses
Description: Immunoturbidimetric assay for determination of serum Cys-C levels and the Chronic Kidney Disease Epidemiology (CKD-EPI) equation for GFR estimation
Study: NCT06799247

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decartes-08
Description: Autologous mRNA CAR T-cell therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drug
Description: infusion without Decartes-08
Study: NCT06793397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYB003
Description: CYB003 is a synthetic psilocybin analog.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYB003
Description: CYB003 is a synthetic psilocybin analog.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Support
Description: Manualized psychological support performed by facilitator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Support
Description: Manualized psychological support performed by facilitator.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychological Support
Description: Manualized psychological support performed by facilitator.
Study: NCT06793527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celiac Plexus Block
Description: During general anesthesia, a celiac plexus block will be performed intraoperatively (20 ml of 0.5% ropivacaine). The patient will not feel discomfort due to general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESP block
Description: Before the procedure, a block of the erector spinae (ESP) compartment will be performed with approximately 20 ml of 0.25% ropivacaine at the Th4 level. The patient will be informed about the possibility of short-term discomfort if the block is performed before full induction of anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidacaine
Description: Instead of a regional block, an intravenous infusion of lidocaine will be used.
Study: NCT06792968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated tablets
Description: 1 tablet of Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated table

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synjardy® 5 mg/1000 mg film-coated tablets
Description: 1 tablet of Empagliflozin+Metformin 5 mg/1000 mg filmcoated tablets
Study: NCT06797531

Intervention type: DRUG
Intervention: ribociclib
Description: This is an observational study. There is no treatment allocation. The decision to initiate ribociclib will be based solely on clinical judgement.
Study: NCT06797063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BEST4Baby
Description: BEST4Baby consists of prenatal and post-delivery breastfeeding education and support for mothers provided by community-based peer counselors who are trained in a modified 5-day WHO/UNICEF Breastfeeding Counselling Course and supported by an mHealth application.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Participants in the control clusters will continue with local practice for antenatal breastfeeding support and referral to facilities. It is expected that they will receive routine health education recommended by the national health system during the prenatal and postnatal period and offered through PHC and community level workers, including ASHAs. ASHAs may visit a woman after delivery to provide lactation support, as needed, with visits ceasing at 42 days post-delivery. Breastfeeding mothers requiring advanced lactation support may be referred to a community subcenter for care with more skilled clinicians.
Study: NCT06796686

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 426c.Mod.Core-C4b
Description: 426c.Mod.Core-C4b is supplied at a concentration of 2 mg/mL, 0.55 mL per vial.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 426c.Mod.Core-C4b
Description: 426c.Mod.Core-C4b is supplied at a concentration of 2 mg/mL, 0.55 mL per vial.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 426c.Mod.Core-C4b
Description: 426c.Mod.Core-C4b is supplied at a concentration of 2 mg/mL, 0.55 mL per vial.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HxB2.WT.Core-C4b
Description: HxB2.WT.Core-C4b is supplied at a concentration of 1 mg/mL, 0.5 mL per vial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HxB2.WT.Core-C4b
Description: HxB2.WT.Core-C4b is supplied at a concentration of 1 mg/mL, 0.5 mL per vial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HxB2.WT.Core-C4b
Description: HxB2.WT.Core-C4b is supplied at a concentration of 1 mg/mL, 0.5 mL per vial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3M-052-AF adjuvant
Description: immune response modifier (IRM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3M-052-AF adjuvant
Description: immune response modifier (IRM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3M-052-AF adjuvant
Description: immune response modifier (IRM)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aluminum hydroxide suspension (Alum) adjuvant
Description: Alhydrogel.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aluminum hydroxide suspension (Alum) adjuvant
Description: Alhydrogel.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aluminum hydroxide suspension (Alum) adjuvant
Description: Alhydrogel.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diluent
Description: Tris-NaCl buffer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diluent
Description: Tris-NaCl buffer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diluent
Description: Tris-NaCl buffer
Study: NCT06793839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Enhanced Ultrasonography localizing microscopy
Description: 3 bilateral transcranial enhanced (with Sonovue) ultrasonography per patient to visualize cranial arteries of the anterior circulation of the brain
Study: NCT06787703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological First Aid Intervention
Description: Psychological first aid is a compassionate and supportive presence designed to mitigate acute distress and asses the need for continued mental health care. The intervention aims to enhance the compassionate presence, assist with needs and promote adaptive functioning. The intervention encompasses seven main themes (RAPID model, emotion stabilization, self-compassion, reframing, instillation of hope and empowerment) that will be covered through a series of five training exercises conducted on 6 sessions. Each session ranged in duration from 30 to 45 minutes.~The program going along the RAPID PFA model, that represents a simple structure of (R for: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition).~The program going along the RAPID PFA model, that represents a simple structure of (R for: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition). The
Study: NCT06791837

Intervention type: BEHAVIORAL
Intervention: EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Description: the obese group only will undergo 4 wk of supervised exercise training
Study: NCT06798233

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non-Ambulatory Hip Pain questionnaire
Description: a new questionnaire for care givers to identify hip pain in pediatric patients with quadriplegia
Study: NCT06796439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching
Description: Participants will be divided into two groups with sample size of 52 participants in each group.~Group 1: Participants will perform static Stretching protocols. There were no special warm-up exercises (running and skipping) after the implementation of static stretching exercises. After the general warm-up, participants would engage in a sequence of randomized static stretches including Lower back stretch, Quads stretch, Hams Stretch, Calf Stretch and Upper limb Stretches (biceps, Triceps, Arm across chest, Arm pull and head tilt, Side stretch, backward arm stretch, Pect. stretch and Towel Stretch). All stretches were done as 3 sets of 30 seconds for 20 minutes for 5 days per week and held at the point of mild discomfort. Readings will be taken after 1st, 3rd and 6th week, respectively.~Group 2: Participants will perform Dynamic Stretching protocols. There were no special warm-up exercises (running and skipping) after the implementation of dynamic stretching exercises. Participants wou

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Stretching
Description: Group 2: Participants will perform Dynamic Stretching protocols. There were no special warm-up exercises (running and skipping) after the implementation of dynamic stretching exercises. Participants would engage in a sequence of randomized static stretches including Jumping Jacks, Lunges, Trunk Circles, arm swings and butt Kicks. All stretches were done as 3 sets of 30 seconds for 20mins for 5 days per week and held at the point of mild discomfort. Readings will be taken after 1st, 3rd and 6th week, respectively.
Study: NCT06379984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Sublingual buprenorphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Sublingual buprenorphine